September 11, 2019 / 2:37 PM / a month ago

BRIEF-Idorsia Says Janssen Reports Phase 3 Study Data For Ponesimod

Sept 11 (Reuters) - IDORSIA LTD:

* JANSSEN REPORTS NEW HEAD-TO-HEAD PHASE 3 STUDY DATA SHOW PONESIMOD SUPERIORITY VERSUS AUBAGIO (TERIFLUNOMIDE) 14 MG IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

* IDORSIA PHARMACEUTICALS LTD, J&J AND ACTELION PHARMACEUTICALS LTD HAVE A REVENUE SHARING AGREEMENT IN RESPECT TO PONESIMOD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below